GlassScriptPhysician profile
Jacqueline D Tebeest
NPI 1831591684
$1,368.12
in general payments reported to CMS, 2019-2025
25 companies · $663 in 2025
The $663 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.77 · 2022: $31.73 · 2023: $100 · 2024: $553 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,316.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $341.26 | 2022-2025 | |
| Pfizer INC. | $109.12 | 2024-2025 | |
| Lilly USA, LLC | $103.11 | 2024-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $102.24 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $92.57 | 2023-2025 | |
| Amgen INC. | $63.18 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $62.47 | 2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $60.84 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $52.26 | 2022-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $36.32 | 2023-2024 | |
| Esperion Therapeutics, INC. | $35.00 | 2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $33.68 | 2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.47 | 2025 | Caplyta |
| Astellas Pharma US INC | $30.29 | 2023-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $26.43 | 2025 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $23.92 | 2024 | |
| Corcept Therapeutics | $22.75 | 2023 | Korlym |
| Ascensia Diabetes Care US INC. | $19.97 | 2025 | |
| Philips North America LLC | $19.77 | 2021 | |
| Insulet Corporation | $19.56 | 2025 | Omnipod |
| Ironwood Pharmaceuticals, INC | $19.48 | 2024 | |
| Phathom Pharmaceuticals, INC. | $16.54 | 2024 | Voquezna |
| Viatris Specialty LLC | $16.00 | 2025 | Yupelri |
| Exact Sciences Corporation | $15.05 | 2025 | Cologuard Collection Kit |
| Electromed, INC. | $13.84 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Tebeest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.